Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2020/12/029600
CTRI/2020/12/029600
Completed
N/A

A Clinincal study to assess the efficacy and safety of an ayurvedic polyherbal formulation in the management of flu like symptoms - FLUVA

Clinfound Clinical Research Services Pvt Ltd0 sites30 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealth Condition 1: J111- Influenza due to unidentified influenza virus with other respiratory manifestations

Overview

Phase
N/A
Intervention
Not specified
Conditions
Health Condition 1: J111- Influenza due to unidentified influenza virus with other respiratory manifestations
Sponsor
Clinfound Clinical Research Services Pvt Ltd
Enrollment
30
Status
Completed
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
November 26, 2020
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Clinfound Clinical Research Services Pvt Ltd

Eligibility Criteria

Inclusion Criteria

  • •Suffering from fever in URTI up to 7 days with associated secondary symptoms
  • •(which may or may not be present)
  • •i.e., headache (Å?iroÅ?Å«la)
  • •pain in joints and muscle (parbaveá¸?)
  • •malaise\-catarrh (staÄ«miá¹­ya),
  • •uneasy breathing (Å?vÄ?sa),
  • •cough (kÄ?sa),
  • •running nose (pratÄ«Å?yaya)
  • •loss of appetite (arÅ«chi)

Exclusion Criteria

  • •Patients with temperature more than 390C (i.e., \>102\.20F), abnormal
  • •pulmonary findings, pleuritis, pneumonia, bronchitis, using warfarin,
  • •antibiotics and/or anti\-inflammatory drugs, hypersensitivity to
  • •NSAIDs, history of trauma, malignancy, diabetes mellitus, high blood
  • •pressure, severe systemic and organ disorders, peptic ulcer syndrome,
  • •bleeding tendency, major surgery and chronic fever (like malaria,
  • •typhoid, tuberculosis etc.), pregnant and lactating females, patients
  • •with alcoholism or who were heavy smokers ( \>20 cigarettes a day)

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, Not Recruiting
Phase 1
Clinical study to evaluate the efficacy, safety and kinetics of Octagam® 10% for replacement therapy in Primary Immunodeficiency Diseases (PID) - NAPrimary Immundeficiency Diseases (PID)MedDRA version: 9.1 Level: LLT Classification code 10064859 Term: Primary immunodeficiency syndrome
EUCTR2007-002611-27-GBOctapharma AG5
Active, Not Recruiting
Phase 1
Clinical study to evaluate the efficacy, safety and kinetics of Octagam® 10% for replacement therapy in Primary Immunodeficiency Diseases (PID) - NAPrimary Immunodeficiency Diseases (PID)MedDRA version: 9.1Level: LLTClassification code 10064859Term: Primary immunodeficiency syndrome
EUCTR2007-002611-27-FROctapharma AG5
Active, Not Recruiting
N/A
Clinical study to evaluate the efficacy, safety and kinetics of Octagam® 10% for replacement therapy in Primary Immunodeficiency Diseases (PID) - NAPrimary Immundeficiency Diseases (PID)MedDRA version: 9.1Level: LLTClassification code 10064859Term: Primary immunodeficiency syndrome
EUCTR2007-002611-27-DEOctapharma AG45
Completed
N/A
Clinical study to evaluate the efficacy, safety and kinetics of Octagam® 10% for replacement therapy in primary immunodeficiency diseasesPrimary immunodeficiency diseases (PID)Haematological DisordersOther immunodeficiencies
ISRCTN63491981Octapharma AG (Switzerland)45
Completed
Phase 2
To Find the Effect of LION�S MANE POWDER as Nutritional Supplement.Health Condition 1: E648- Sequelae of other nutritional deficiencies
CTRI/2022/03/040724DXN Manufacturing India Pvt Ltd24